David Elder
How to Predict the Absorption Rate of New Chemical Entities
February 23 by Pharmaceuticals & Biotechnology EditorCurrent estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory B...
Predictions for Targeted Drug Delivery with David Elder and Brendan Griffin
December 05 by Andrea CharlesIn this Pharma IQ interview David Elder, Director of Product Development, GlaxoSmithKline and Brendan Griffin Lecturer in Pharmaceutics and Course Director University College Cork, discuss how th...
Formulation Strategy: Five Years From Now
February 24 by David ElderWhat would you say are the main benefits of employing early formulation testing? Most small or virtual biopharm companies try to progress their asset as quickly as possible to a clinical decision mak...
Big Formulation Breakthroughs
February 17 by Andrea CharlesDavid Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins Andrea Charles from Pharma IQ, to discuss the most critical unmet drug delivery need an...
Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK
June 11 by Pharmaceuticals & Biotechnology EditorDrug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities
June 11 by Pharmaceuticals & Biotechnology EditorDrug Discovery and the Market Today Part 4: Developing Amorphous Forms
June 11 by Pharmaceuticals & Biotechnology EditorDrug Discovery and the Market Today Part 3: The Focus on Solubility
June 09 by Pharmaceuticals & Biotechnology EditorDrug Discovery and the Market Today Part 2: Critical Thoughts on Stability
June 09 by Pharmaceuticals & Biotechnology EditorWhat are the 7 Deadly Sins of Quality Assurance and Quality Control? Download our free QA QC eBook now to find out!